GSK 4077164A
Alternative Names: GSK-4077164; GSK-4077164A; iNTS; iNTS-TCV; iNTS-typhoid conjugate vaccine – GlaxoSmithKline Biologicals; Salmonella vaccine - GlaxoSmithKline BiologicalsLatest Information Update: 06 Feb 2024
At a glance
- Originator GlaxoSmithKline Biologicals
- Class Bacterial vaccines; Conjugate vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Salmonella infections; Typhoid
Most Recent Events
- 06 Feb 2024 Phase-II clinical trials in Typhoid (Prevention) (IM) prior to February 2024 (GlaxoSmithKline pipeline, February 2024)
- 15 Jan 2024 Phase-II clinical trials in Salmonella infections (In infants, In children, In adolescents, In adults, Prevention) in Ghana (IM) (NCT06213506)
- 08 Nov 2023 Phase-I clinical trials in Typhoid (Prevention) in Malawi (IM) (NCT05480800)